Navigation Links
Diobex Announces Successful Completion of Phase 2a Trial Of,DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes

for toxicity. DIO-902 has been proven to be both more effective and safer than the racemic mixture in preclinical studies.

"We are delighted with the preliminary data that we have generated to date, and at the prospect of taking the leading Cortisol Synthesis Inhibitor to the next level of clinical development. DIO-902 is clearly at the head of the pack in the advancement of this exciting new drug category," commented Daniel Green, DiObex President.

"DIO-902 offers the possibility of adding a new therapy to the armamentarium which may have an impact on the underlying cause of type 2 diabetes. The prospect of significantly reducing multiple cardiac risk factors with a single drug is an extremely attractive opportunity to enhance patient compliance and convenience while reducing the need for polypharmacy," said Bernice Welles, M.D., Vice President of Development at DiObex.

DiObex plans on initiating a 16-week phase 2b dose-ranging study with DIO- 902 in mid 2007.

About DiObex

DiObex, Inc. is a San Francisco-based biopharmaceutical company founded to develop novel products for the treatment of metabolic diseases. DiObex has two products preparing to enter Phase 2b clinical development. DIO-901 is a formulation of Very Low Dose Glucagon (VLD Glucagon) for reducing or preventing of insulin induced hypoglycemia. DIO-901 has received Fast Track status from the Food and Drug Administration. DIO-902 is a single enantiomer of ketoconazole and is a novel cortisol synthesis inhibitor. Abnormalities in cortisol activity may play an important role in the development of metabolic syndrome, a constellation of conditions that place people at high risk for type-2 diabetes and cardiovascular disease. For more information, visit www.diobex.com.

CONTACT: Daniel Green of DiObex, Inc., +1-415-551-4114, dgreen@diobex.com

Web site: '"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/23/2013)... -- More than half of women diagnosed with early ... still have excellent outcomes. To educate women, Agendia, Inc. ... sources of online consumer information about breast cancer genomic ... recently diagnosed women with information sources, to help them ... "We anticipate these innovative social media campaigns will encourage ...
(Date:5/23/2013)... , May 23, 2013  Texas, premier physician associations ... doctors the survival tools they need to provide demonstrably ... today,s health care marketplace. "I am confident ... local practices," said Stephen L. Brotherton ... " Texas doctors are determined to ...
(Date:5/23/2013)...  Ameritox, the nation,s leader in pain medication ... to become part of its Urine Drug Monitoring ... and improve the clinical outcomes for injured workers. ... manager in the workers, compensation industry, has used ... management strategy for several years. By establishing a ...
Breaking Medicine Technology:Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 2Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 3
... and SAN DIEGO, Nov. 12 Tobira Therapeutics, ... and product discovery for the treatment of life-threatening ... and results from two double-blind, placebo-controlled studies of ... studies, a single-ascending dose (SAD) study and the ...
... , BOTHELL, Wash., Nov. 11 ... ), a global leader in automated external defibrillator ( ... appointed Peter Kingma as senior vice president, effective immediately. ... Marver, president and chief executive officer, and oversees the ...
Cached Medicine Technology:Tobira Therapeutics Announces Presentation of TBR-652 Data at European AIDS Conference 2Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 2Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 3Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 4Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 5
(Date:5/24/2013)... The point-of-care (POC) diagnostics market ... the central laboratory, by other healthcare professionals, patient ... by consumers. This includes products that test blood ... and cardiovascular disease and cancer, as well as ... surgical and emergency departments. , Critical analysis and ...
(Date:5/24/2013)... is available in German . ... "alpha-synuclein" aggregates and accumulates within neurons. Specific areas of ... and advances. The mechanism underlying this pathological progression is ... protein (or abnormal forms of it) along nerve projections ... the German Center for Neurodegenerative Diseases (DZNE) in Bonn ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 On May ... seventh commencement ceremony of American University of Antigua ... in Lincoln Center. , This was the largest graduating ... ceremonies Dick Woodward, AUA’s Senior Vice President for Enrollment ... and Dr. Reza Sanii, Associate Dean of Students and ...
(Date:5/24/2013)... (HealthDay News) -- Nearly three out of four ... and diarrhea, but these issues don,t significantly affect ... Researchers from Loyola University Medical Center in ... due to physiological and hormonal changes that occur ... pregnancy also can play a role. The study ...
(Date:5/24/2013)... 24, 2013 According to the new ... Global Forecasts (2011 - 2016)” published by MarketsandMarkets, global ... million by the end of year 2010 and is ... a CAGR of 17.9% from 2011 to 2016. , ... , 44 Figures , 370 ...
Breaking Medicine News(10 mins):Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 3Health News:Proteins in migration 2Health News:Proteins in migration 3Health News:Proteins in migration 4Health News:AUA Celebrates Seventh Annual Commencement Ceremony 2Health News:Bowel Issues Affect 3 Out of 4 Pregnant Women 2Health News:Micro Irrigation System Market to Reach $3414.7 Million by 2016 at a CAGR of 17.9% - New Report by MarketsandMarkets 2Health News:Micro Irrigation System Market to Reach $3414.7 Million by 2016 at a CAGR of 17.9% - New Report by MarketsandMarkets 3
... to vaccinate put others at risk, researcher says , MONDAY, ... trip to Switzerland in 2008 ended up as a public ... was intentionally unvaccinated against measles, was exposed to the virus ... Diego, he unknowingly exposed a total of 839 people, and ...
... , March 22, 2010 Dr. Rita Colwell ,distinguished Professor from the University of Maryland ... the 2010 Stockholm Water Prize Laureate. Dr. Colwell,s pioneering,research on the prevention of waterborne infectious diseases has helped,protect the ... ... , , ...
... , at the newly opened Rise Club , 6801 W. Hollywood Blvd., Hollywood, CA. , ... , , ... ... "We,ve walked for it, we,ve run ...
... children in schools across the country, and employees of workplaces nationwide will wear purple to support epilepsy awareness on March 26 . Thousands of Americans will also join the ... ... ... ...
... Representatives showed they have heard the voice of America,s families by passing the Patient Protection and Affordable Care Act and sending it ... the nation,s leading Hispanic health advocacy group. , ... ... ...
... ... Online Communications Program , ... (PRWEB) March 22, 2010 -- The Society for New Communications Research ( http://sncr.org ... latest developments in media and communications, today announced that it has received a $200,000 ...
Cached Medicine News:Health News:Measles Outbreak Triggered by Unvaccinated Child 2Health News:Measles Outbreak Triggered by Unvaccinated Child 3Health News:American Public Health Champion Receives 2010 Stockholm Water Prize 2Health News:American Public Health Champion Receives 2010 Stockholm Water Prize 3Health News:MAYO Communications Retained by MAMMOJAM 2010 Dr. Susan Love Research Foundation Event 2Health News:MAYO Communications Retained by MAMMOJAM 2010 Dr. Susan Love Research Foundation Event 3Health News:Purple Day March 26th: The United States Goes Purple in Support of Epilepsy Awareness 2Health News:Purple Day March 26th: The United States Goes Purple in Support of Epilepsy Awareness 3Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Reconciliation Bill 2Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Reconciliation Bill 3Health News:Society for New Communications Research Receives Grant to Help Raise Awareness and Reduce Racial and Ethnic Health Disparities 2Health News:Society for New Communications Research Receives Grant to Help Raise Awareness and Reduce Racial and Ethnic Health Disparities 3Health News:Society for New Communications Research Receives Grant to Help Raise Awareness and Reduce Racial and Ethnic Health Disparities 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: